Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Yvonne A Efebera, M.D., Kristina Humphries, M.S., Don M. Benson, Jr., MD, PhD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Steven M. Devine, MD

Blood (2012) 120 (21): 3114.

https://doi.org/10.1182/blood.V120.21.3114.3114

Published: 2012

Journal Articles

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Craig C. Hofmeister, MD, Zhongfa Liu, Ph.D., Mindy A Bowers, BS, Pierluigi Porcu, MD, Joseph M. Flynn, DO, MPH, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Don M. Benson, Jr., MD, PhD, Leslie A Andritsos, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Susan Geyer, PhD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2012) 120 (21): 2955.

https://doi.org/10.1182/blood.V120.21.2955.2955

Published: 2012

Journal Articles

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Anissa Bingman, M.S., Gerard Lozanski, M.D., Robert A. Baiocchi, M.D., Ph.D., William Falk, B.S., Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, M.D., Kristina Humphries, M.S., Megan Sell, RN, MS, Carli N Greenfield, RN, MSN, ACNP, Mark E Lustberg, MD, PhD, John L. Vaughn, BS, Christian Tyler Earl, Susan Geyer, PhD, Steven M. Devine, MD

Blood (2012) 120 (21): 4460.

https://doi.org/10.1182/blood.V120.21.4460.4460

Published: 2012

Journal Articles

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Robert A. Baiocchi, M.D., Ph.D., Gerard Lozanski, M.D., Kristina Humphries, M.S., Kristie A. Blum, MD, Pierluigi Porcu, MD, Sam Penza, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Christian Tyler Earl, Joseph Zitesman, B.S., Carl Quinion, Mark E Lustberg, MD, PhD, Leslie A Andritsos, MD, Steven M. Devine, MD

Blood (2012) 120 (21): 2004.

https://doi.org/10.1182/blood.V120.21.2004.2004

Published: 2012

Journal Articles

Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.

Craig C. Hofmeister, MD, Gisele Rieser, RN, Mindy A Bowers, BS, Lisa C Merritt, RN, BSN, Carli N Greenfield, RN, MSN, ACNP, Yvonne A Efebera, MD, Don M Benson, Jr., MD, Steven M Devine, MD, Janet S de Moor, MPH, PhD

Blood (2010) 116 (21): 3807.

https://doi.org/10.1182/blood.V116.21.3807.3807

Published: 2010

Journal Articles

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Jr, Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne Efebera, Brian Becknell, Robert A. Baiocchi, Jianying Zhang, Jianhua Yu, Megan K. Smith, Carli N. Greenfield, Pierluigi Porcu, Steven M. Devine, Rinat Rotem-Yehudar, Gerard Lozanski, John C. Byrd, Michael A. Caligiuri

Blood (2010) 116 (13): 2286–2294.

https://doi.org/10.1182/blood-2010-02-271874

Published: 2010

Includes: Supplemental data

Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD

Blood (2009) 114 (22): 4641.

https://doi.org/10.1182/blood.V114.22.4641.4641

Published: 2009

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 3870.

https://doi.org/10.1182/blood.V114.22.3870.3870

Published: 2009

NARROW

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only